Authors
Latest:
Avelumab Maintenance for Urothelial Carcinoma: Real-World EvidenceDaniel Petrylak, MD and Donald Barry Boyd, MD, MS, examine real-world data presented in the recent publication, “Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.”
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With CancerABSTRACT Adolescents and young adults (AYAs) with cancer constitute approximately 70,000 patients diagnosed each year. Survival rates for AYAs with cancer have increased steadily in recent decades due to improvements in therapeutic regimens and early detection. Given the large and growing number of AYA cancer survivors, additional research is needed on the immediate and long-term psychosocial support required for this population including family planning and fertility. Fertility and fertility preservation in female AYAs, in particular, is historically understudied and has psychologically relevant ramifications distinct from male AYAs. Decision science can contribute to this area of oncological care and has implications for clinical encounters and research concerning female AYA patients with cancer. Patient-centered care and shared decision-making that integrates recent research regarding fertility preservation in the context of cancer treatment can improve outcomes for AYA cancer survivors.
Latest:
Putting Amivantamab Plus Lazertinib Into PracticePanelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.
Latest:
Metastatic Renal Cell Carcinoma With Sarcomatoid FeaturesIn this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.
Latest:
Revumenib Shows Efficacy and Safety in R/R KMT2Ar Acute LeukemiaRevumenib treatment results in durable MRD-negative remissions in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia in the phase 2 Augment-101 study.
Latest:
Key Takeaways on the Clinical Utility of ctDNA in Colorectal CancerStacey A. Cohen, MD, and Daniel H. Ahn, DO, share their key takeaways on the clinical utility of ctDNA in the treatment of patients with colorectal cancer.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Using Genetic Information to Guide Precision Medicine and Personalized Treatment in Prostate Cancer: Expert Perspectives on an Evolving LandscapeDwight E. Heron, MD, MBA, FACRO, FACR discusses how advanced multi-omics approaches, personalized precision medicine techniques, artificial intelligence–driven genetic interpretation tools, and emerging gene editing technologies such as CRISPR (clustered regularly interspaced short palindromic repeats) are poised to revolutionize clinical practice by enabling more targeted diagnostics, predictive risk assessments, and individualized treatment strategies across oncology, rare disease management, and chronic condition prevention.
Latest:
Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple MyelomaInvestigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
Latest:
Considering Dosing and AE Management Strategies With Tarlatamab in SCLCExperts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Latest:
Treatment Experience for a Patient With GVHDA patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.
Latest:
Future of R/R MM: Emerging AgentsIn this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
Latest:
Primary Focal Therapy for Localized Prostate Cancer: A Review of the LiteratureFocal therapy for prostate cancer could balance undertreatment and overtreatment of localized prostate cancer for highly selected patients. Long-term oncologic outcomes are not yet available for any modality. Patients should be informed regarding currently available outcomes, the necessity of adherence to a stringent follow-up protocol, and the possible need for additional targeted therapy or future radical treatment in case of recurrence.
Latest:
Tagraxofusp in BPDCN: Practical Advice and Future Directions in CareAfter sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.
Latest:
Roger Li, MD, Talks Future Analyses of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBCRoger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.
